Description
The global Antisense and RNAi Therapeutics Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Antisense Oligonucleotide Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Antisense and RNAi Therapeutics Drug include Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch & Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics and Akcea Therapeutics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
This report aims to provide a comprehensive presentation of the global market for Antisense and RNAi Therapeutics Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antisense and RNAi Therapeutics Drug. This report contains market size and forecasts of Antisense and RNAi Therapeutics Drug in global, including the following market information:
Global Antisense and RNAi Therapeutics Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antisense and RNAi Therapeutics Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antisense and RNAi Therapeutics Drug Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Antisense and RNAi Therapeutics Drug Market Segment Percentages, by Type, 2022 (%)
Antisense Oligonucleotide
Aptamer
Other
Global Antisense and RNAi Therapeutics Drug Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Antisense and RNAi Therapeutics Drug Market Segment Percentages, by Application, 2022 (%)
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
Global Antisense and RNAi Therapeutics Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Antisense and RNAi Therapeutics Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Antisense and RNAi Therapeutics Drug revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Antisense and RNAi Therapeutics Drug revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Antisense and RNAi Therapeutics Drug, market overview.
Chapter 2: Global Antisense and RNAi Therapeutics Drug market size in revenue.
Chapter 3: Detailed analysis of Antisense and RNAi Therapeutics Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Antisense and RNAi Therapeutics Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
